Competing interests: Dr. Naylor was based at the Institute for Clinical Evaluative Sciences
and Sunnybrook and Women's College Health Sciences Centre until the summer of 1999 …

In summing up, Shuchman suggests that Olivieri's concerns about deferiprone may have
heavily influenced the drug-licensing bodies in the USA and Canada such that many …

A recent study by Olivieri et al, published in PLOS ONE, reports that between 2009 and 2015
a third of patients with thalassaemia in Canada's largest hospital were switched from first …

The editorial by GJ Kontoghiorghes [1] contains significant factual inaccuracies, selectively
omits important information about deferasirox and lacks the robust epidemiological …

Each month, subscribers to The Formulary Monograph Service receive five to six well-
documented monographs on drugs that are newly released or are in late phase 3 trials. The …

ON JUNE 28, 1993, the US Supreme Court handed down a decision that, in the words of
one commentator," could affect almost every piece of litigation in the Federal courts from this …

Supreme Court decided that Rule 702 of the Federal Rules of Evidence requires an initial
detennination by the trial court that" scientific" evidence is" reliable." Ironically, the Daubert …

The story of the battle between Dr. Nancy Olivieri and the drug company Apotex is well
known: the company produced an experimental drug, deferiprone, that was used to treat …

This JOURNAL has avoided criticizing the FDA for its weaknesses and its failings because
we have feIt that it is charged with a virtually impossible job. Certain recent actions of the …

Materials and Methods The purpose of this analysis is to examine the association between
HU treatment and pain or ACS episodes and service costs over time in routine clinical …